Clinical Advisory Board

Richard L. Schilsky

Member of the Clinical Advisory Board since April 2021

Education: MD, FACP, FSCT, FASCO

Background: Professor emeritus at the University of Chicago having recently retired from his position as Executive Vice President and Chief Medical Officer (CMO) of ASCO. Dr. Schilsky is also a past President of ASCO, having served in the role during 2008-2009, and former Board member of Conquer Cancer, the ASCO Foundation. Before joining ASCO in 2013, Dr. Schilsky spent the majority of his career at the University of Chicago where he joined the faculty in 1984. He is a highly respected leader in the field of clinical oncology and specializes in new drug development and treatment of gastrointestinal cancers.


Peter Michael Vestlev

Chief Medical Officer at Scandion Oncology and Chair of the Clinical Advisory Board

Education: MD, CBA, MPP

Background: Chief Physician, Oncologist, Region Zealand and Capital Region Previously, Head of Radiotherapy unit, Herlev Hospital, Head of Cooperating Cancer Departments, Head of research unit Roskilde Hospital, consultant for the Danish Medicines Agency, Chief Oncologist Capital Region.


Nils Brünner

Member of the Clinical Advisory Board since 2021

Education: MD, DMSc.

Background: Professor emeritus at University of Copenhagen and recently retired from his position as co-founder, CEO and CSO of Scandion Oncology A/S. Dr Brünner is former BoD member and Chairman for Preclinical Research, EORTC. Dr Brünner had his basic medical training in medical oncology at hospitals in Greater Copenhagen supplemented with an education in cellular and molecular biology from the National Cancer Institute and Georgetown University, USA. Dr Brünner has published more than 400 peer-reviewed scientific papers on translational cancer research.

Pipeline

Scandion Oncology has two promising compounds in the pipeline. SCO-101, our most advanced lead candidate, is in clinical Phase I and II studies and SCO-201 is in preclinical testing. We expect to deliver proof-of-concept with SCO-101 in 2022. Scandion Oncology is building a pipeline of drugs that can revert anti-cancer drug resistance through different mechanisms. The aim is to increasingly broaden the offering of medicines able to combat anti-cancer drug resistance. 

Clinical Trials

Our first-in-class lead compound SCO-101 has been shown to enhance the effect of certain standard chemotherapies when given in combination. Scandion Oncology has two programs in clinical development with SCO-101. The most advanced program, CORIST, for the treatment of drug resistant metastatic colorectal cancer is in clinical Phase II studies. The second program, PANTAX, for the treatment of inoperable or metastatic pancreatic cancer is in clinical Phase Ib studies.

Investors

Detailed analyses suggest the market for Scandion Oncology’s products to be more than EUR 4 billion annually.

We believe our programs could be attractive for various pharmaceutical companies to combine with their anti-cancer treatments.